propafenone has been researched along with Malaria in 3 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previously reported studies identified analogues of propafenone that had potent antimalarial activity, reduced cardiac ion channel activity, and properties that suggested the potential for clinical development for malaria." | 7.78 | Lead optimization of antimalarial propafenone analogues. ( Clark, JA; Connelly, MC; Derisi, JL; Furimsky, A; Gow, J; Guiguemde, WA; Guy, RK; Iyer, LV; Kyle, DE; Lemoff, A; Lowes, D; Mirsalis, J; Parman, T; Pradhan, A; Sigal, M; Tang, L; Wilson, E; Zhu, F, 2012) |
| "Previously reported studies identified analogues of propafenone that had potent antimalarial activity, reduced cardiac ion channel activity, and properties that suggested the potential for clinical development for malaria." | 3.78 | Lead optimization of antimalarial propafenone analogues. ( Clark, JA; Connelly, MC; Derisi, JL; Furimsky, A; Gow, J; Guiguemde, WA; Guy, RK; Iyer, LV; Kyle, DE; Lemoff, A; Lowes, D; Mirsalis, J; Parman, T; Pradhan, A; Sigal, M; Tang, L; Wilson, E; Zhu, F, 2012) |
| " The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity." | 1.37 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. ( Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Plouffe, D | 1 |
| Brinker, A | 1 |
| McNamara, C | 1 |
| Henson, K | 1 |
| Kato, N | 2 |
| Kuhen, K | 1 |
| Nagle, A | 2 |
| Adrián, F | 1 |
| Matzen, JT | 1 |
| Anderson, P | 1 |
| Nam, TG | 2 |
| Gray, NS | 1 |
| Chatterjee, A | 2 |
| Janes, J | 1 |
| Yan, SF | 1 |
| Trager, R | 1 |
| Caldwell, JS | 1 |
| Schultz, PG | 2 |
| Zhou, Y | 2 |
| Winzeler, EA | 2 |
| Meister, S | 1 |
| Plouffe, DM | 1 |
| Kuhen, KL | 1 |
| Bonamy, GM | 1 |
| Wu, T | 1 |
| Barnes, SW | 1 |
| Bopp, SE | 1 |
| Borboa, R | 1 |
| Bright, AT | 1 |
| Che, J | 1 |
| Cohen, S | 1 |
| Dharia, NV | 1 |
| Gagaring, K | 1 |
| Gettayacamin, M | 1 |
| Gordon, P | 1 |
| Groessl, T | 1 |
| Lee, MC | 1 |
| McNamara, CW | 1 |
| Fidock, DA | 1 |
| Richmond, W | 1 |
| Roland, J | 1 |
| Rottmann, M | 1 |
| Zhou, B | 1 |
| Froissard, P | 1 |
| Glynne, RJ | 1 |
| Mazier, D | 1 |
| Sattabongkot, J | 1 |
| Tuntland, T | 1 |
| Walker, JR | 1 |
| Diagana, TT | 1 |
| Lowes, D | 1 |
| Pradhan, A | 1 |
| Iyer, LV | 1 |
| Parman, T | 1 |
| Gow, J | 1 |
| Zhu, F | 1 |
| Furimsky, A | 1 |
| Lemoff, A | 1 |
| Guiguemde, WA | 1 |
| Sigal, M | 1 |
| Clark, JA | 1 |
| Wilson, E | 1 |
| Tang, L | 1 |
| Connelly, MC | 1 |
| Derisi, JL | 1 |
| Kyle, DE | 1 |
| Mirsalis, J | 1 |
| Guy, RK | 1 |
3 other studies available for propafenone and Malaria
| Article | Year |
|---|---|
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug | 2008 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resista | 2011 |
Lead optimization of antimalarial propafenone analogues.
Topics: Administration, Oral; Animals; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Cytochrome P-450 | 2012 |